HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MDX-1401

a fully human anti-CD30 mAb for treatment of Hodgkin's lymphoma

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Assad, Albert: 1 article (05/2009)
2.	Black, Amelia: 1 article (05/2009)
3.	Cardarelli, Pina M: 1 article (05/2009)
4.	Chen, Sharline: 1 article (05/2009)
5.	Chen, Tseng-Hui: 1 article (05/2009)
6.	Graziano, Robert F: 1 article (05/2009)
7.	King, David J: 1 article (05/2009)
8.	Kuhne, Michelle R: 1 article (05/2009)
9.	Liu, Jie: 1 article (05/2009)
10.	Moldovan-Loomis, Maria-Cristina: 1 article (05/2009)

Related Diseases

1.	Neoplasms (Cancer) 05/15/2009 - "Furthermore, MDX-1401 was efficacious in inhibiting tumor growth in CD30(+) lymphoma xenografts. "
2.	Lymphoma (Lymphomas) 05/15/2009 - "The low doses of antibody required for ADCC activity irrespective of donor genotype, the ability to mediate ADCC in target cells expressing low levels of CD30, and increased in vivo efficacy support the development of MDX-1401 for treatment of malignant lymphoma." 05/15/2009 - "In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma." 05/15/2009 - "Furthermore, MDX-1401 was efficacious in inhibiting tumor growth in CD30(+) lymphoma xenografts. "

Related Therapies and Procedures

1.	Therapeutics